Shield Therapeutics (LON:STX) Stock Price Passes Below 50-Day Moving Average – Should You Sell?

Shield Therapeutics plc (LON:STX) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 7.48 and traded as low as GBX 6.50. Shield Therapeutics shares last traded at GBX 6.73, with a volume of 511,992 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt reiterated a “buy” rating and set a GBX 15 price objective on shares of Shield Therapeutics in a research note on Friday, November 7th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of GBX 15.

Shield Therapeutics Stock Performance

The firm’s 50-day moving average price is GBX 7.48 and its two-hundred day moving average price is GBX 5.09. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The firm has a market capitalization of £71.41 million, a price-to-earnings ratio of -3.36 and a beta of 1.42.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.